Professional Development

Valeant and Allergan continue to joust, Santen purchases MSD’s ophthalmology drug portfolio in selected markets, and Kala completes a US$22.5 million Series B financing round

Purchase of the ex-US rights for Fovista is costing Novartis US$200 million down and up to a cool US$1 billion in milestone payments

Sitting Down With Alice McPherson,founder of the Retina Research Foundation

Increasing the light intensity over the thinnest point of the cornea – the periphery –improves outcomes of corneal collagen cross-linking in keratectasia patients.

A new technology that measures subjective refraction based on point spread function targets generates better data, increases efficiency in the clinic and improves patient outcomes.

People with learning disabilities are ten times more likely to have serious sight problems than the general population and often fail to receive the same standard of care. Here’s how to avoid some of the pitfalls and some tips for a successful doctor-patient relationship.

If you had your time again, would you go to medical school, and would you choose ophthalmology?

To shave $2.7 billion from costs there will be substantial cuts and job losses

Certain patients don't get the treatment that they need. A little understanding and forward planning can solve the problem.

Sitting Down With Dan Myers, President and CEO of Alimera Sciences, Inc.